Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04689932 · ClinicalTrials.gov registry record · Phase 4

Triferic AVNU Infusion Via Freedom Pump During Hemodialysis

A Phase 4 study of End Stage Renal Disease, sponsored by Rockwell Medical Technologies.

Completed
Registry status
Phase 4
Development phase
12
Enrollment target
1
Study location

NCT04689932 is a Phase 4 study of End Stage Renal Disease that has completed, run by Rockwell Medical Technologies. The registered enrollment target is 12 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04689932, a Phase 4 study of End Stage Renal Disease, has completed, sponsored by Rockwell Medical Technologies.

COMPLETED
Registry status
Phase 4
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this study is to evaluate the delivery of Triferic AVNU intravenously using the Freedom Pump-20 during hemodialysis into the pre-dialyzer and post-dialyzer blood lines.

Conditions Studied

Interventions

  • DRUG Triferic AVNU

Study Locations (1)

Texas

  • Luxury Dialysis - Webster

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2021-04-19
Est. Completion 2021-06-19
Phase Phase 4

Sponsor

Rockwell Medical Technologies

15 total trials

What the Registry Record Tells You About NCT04689932

The ClinicalTrials.gov registry entry for NCT04689932 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower). The listed sponsor is Rockwell Medical Technologies, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Triferic AVNU is the first listed.

NCT04689932 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04689932 about?

NCT04689932 is a clinical study titled "Triferic AVNU Infusion Via Freedom Pump During Hemodialysis". The main purpose of this study is to evaluate the delivery of Triferic AVNU intravenously using the Freedom Pump-20 during hemodialysis into the pre-dialyzer and post-dialyzer blood lines.

What is the current status of trial NCT04689932?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2021-04-19. Estimated completion is 2021-06-19.

What conditions does trial NCT04689932 study?

This clinical trial studies the following conditions: End Stage Renal Disease.

What interventions are being tested in trial NCT04689932?

The interventions under investigation include: Triferic AVNU (DRUG).

Who is sponsoring clinical trial NCT04689932?

This trial is sponsored by Rockwell Medical Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04689932 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for End Stage Renal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.